case of the successful use of the immunotherapy

[Olga]

Immunotherapy related artcile from the Immunotherapy Laboratory, St. Vincent Medical Center, Los Angeles, California published in Breast J. 2006 Sep-Oct;12(5):475-80. :

Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim.

http://www.ncbi.nlm.nih.gov/entrez/quer ... med_docsum

Interesting the fact that after initial regression of the mets while under the vaccine treatment the patient experienced the progression and reinstitution of vaccine inoculation resulted in major regression of the brain and breast lesions, improvement in all other areas, and no indication of new lesions. They used a complex approach to the vaccination - Each treatment was preceded 48 hours earlier with low-dose cyclophosphamide 300 mg/m(2) to abrogate regulatory T-cell activity. Interferon (IFN)-alpha, 20,000 IU, was injected into each inoculation site at 48 and 96 hours postinoculation to provide an additional "danger signal." The vaccine was allogenic, not from the patient's tumour but from the cell line.